Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles - Investor's Business Daily
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, a deal framed by STAT as emblematic of a booming biotech M&A market.
- Crinetics Pharmaceuticals (ticker CRNX) saw its stock roughly double on the acquisition news, per Investor's Business Daily.
Why it matters: Vertex is paying $10 billion in cash and/or deal value for Crinetics, and the immediate market response — a near-doubling of CRNX — shows investors are pricing in a meaningful premium. The deal also lifts related biotech tickers (CRNX, D, BCRX) to 52-week highs, per Yahoo Finance, signaling that one large pharma acquisition is rippling across the biotech sector.
